Nanobiotix (NASDAQ: NBTX) shows promising early NBTXR3 lung cancer data

Rhea-AI Filing Summary

Nanobiotix S.A. furnished a press release highlighting first data from the Johnson & Johnson–sponsored randomized Phase 2 CONVERGE study of JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer. Investigators reported an acceptable safety profile with no serious treatment-emergent adverse events and no impact on patients’ ability to continue planned therapy.

Among 7 patients evaluated after concurrent chemoradiotherapy and before anti-PD-L1 treatment, initial efficacy signals were encouraging, with an objective response rate of 71.4% and disease control rate of 100%, compared with an estimated 45–50% response benchmark. JNJ-1900 (NBTXR3) is a one-time intratumoral hafnium oxide nanoparticle radioenhancer activated by radiotherapy and is being developed across multiple solid tumors, including a global Phase 3 head and neck cancer trial and a global co-development agreement with Janssen.

Insights

Biotech clinical-trials analyst

Early Phase 2 lung data are promising but still very preliminary.

The CONVERGE study reports that JNJ-1900 (NBTXR3) plus chemoradiation showed an acceptable safety profile with no serious treatment-emergent adverse events, suggesting the intratumoral procedure and radioenhancer did not disrupt planned therapy in this stage 3 lung cancer setting.

Among 7 evaluable patients, the objective response rate was 71.4% and disease control rate was 100%, compared with a cited 45–50% benchmark. While this gap looks attractive, the sample size is very small and described as early outcomes, so it mainly serves as a signal-generating data point.

JNJ-1900 (NBTXR3) already has a randomized Phase 2/3 proof-of-concept in soft tissue sarcoma and a Fast Track designation in head and neck cancer from the FDA in February 2020. Future readouts from larger randomized cohorts and the ongoing global Phase 3 NANORAY-312 trial will be important to understand whether these early lung cancer results are durable and generalizable.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On March 30, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated March 30, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: March 30, 2026		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

EXHIBIT 99.1

NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference

PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of first data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer, at the 2026 European Lung Cancer Conference.

POSTER #297P: Novel Intratumoral Radioenhancer (JNJ -1900) with Chemoradiation and Consolidative Immunotherapy for Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC): Early Outcomes from the Phase II CONVERGE Study

Benjamin T. Cooper,¹ Jeffrey D. Bradley,² Sushma Patel,³ Michael A. Pritchett,⁴ Steven J. Feigenberg,² Kevin C. Ma,⁵ Isaac Laniado,⁶ Melina E. Marmarelis,⁷ Matthew Scarlotta,⁸ Joshua K. Sabari,⁹ Yi -Wen Ma,¹⁰ Yina Kuang,¹⁰ Kiran Devisetty,¹⁰ Balaji Laxmanan,¹⁰ David M. DiBardino⁵

Study Conclusions

• The procedure demonstrated an acceptable safety profile without serious treatment-emergent adverse events (TEAEs) and did not adversely impact patients’ ability to continue planned therapy
• Initial efficacy responses observed in 7 patients at first disease evaluation following concurrent chemoradiotherapy, and before treatment with anti-PD-L1, are promising (ORR = 71.4%; DCR = 100%) relative to the estimated benchmark (ORR = 45%-50%).

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas through a successful randomized Phase 2/3 study in 2018. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.

Radiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. The program is led by NANORAY-312—a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy—the same population being evaluated in the Phase 3 study.

Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 2, 2025 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 filed on September 30, 2025 which are available on the SEC’s website at www.sec.gov and on the AMF's website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com  Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

 __________________

¹Radiation Oncology, NYU Langone Health, New York, USA; ²Radiation Oncology, University of Pennsylvania, Philadelphia, USA; ³Radiation Oncology, FirstHealth of the Carolinas, Pinehurst, USA; ⁴Interventional Pulmonology, FirstHealth of the Carolinas, Pinehurtst, USA; ⁵University of Pennsylvania, Philadelphia, USA; ⁶Interventional Pulmonology, NYU Langone Health, New York, USA; ⁷Medical Oncology, University of Pennsylvania, Philadelphia, USA; ⁸Medical Oncology, FirstHealth of the Carolinas, Pinehurst, USA; ⁹Medical Oncology, NYU Langone Health, New York, USA; ¹⁰Johnson & Johnson, New Brunswick, NJ, USA

Attachment

• 2026-03-30 -- NBTX -- Ph2 NBTXR3 in Sage 3 inoperable NSCLC @ 2026 ELCC -- FINAL (https://ml.globenewswire.com/Resource/Download/0563dabb-a2a1-4e48-9dfe-d7a61b202b7d)

FAQ

What did Nanobiotix (NBTX) announce in this Form 6-K?

Nanobiotix reported that Johnson & Johnson presented first data from the randomized Phase 2 CONVERGE trial of JNJ-1900 (NBTXR3) in stage 3 inoperable lung cancer, showing acceptable safety and encouraging early efficacy signals at the 2026 European Lung Cancer Conference.

What are the early efficacy results for JNJ-1900 (NBTXR3) in lung cancer?

Early data in 7 patients showed an objective response rate of 71.4% and disease control rate of 100% after concurrent chemoradiotherapy. These responses preceded anti-PD-L1 treatment and are described as promising relative to an estimated 45–50% response benchmark in this patient population.

How was the safety profile of JNJ-1900 (NBTXR3) described in the CONVERGE study?

Investigators reported that the JNJ-1900 (NBTXR3) procedure had an acceptable safety profile with no serious treatment-emergent adverse events. Importantly, treatment did not interfere with patients’ ability to continue their planned therapy, supporting feasibility alongside standard chemoradiation and subsequent immunotherapy.

What is JNJ-1900 (NBTXR3) and how does it work?

JNJ-1900 (NBTXR3) is a nanotechnology-based oncology product made of functionalized hafnium oxide nanoparticles delivered by a one-time intratumoral injection. It is activated by radiotherapy to enhance local tumor cell death and is designed to trigger adaptive immune responses and long-term anti-cancer memory in solid tumors.

In which other cancers is Nanobiotix developing JNJ-1900 (NBTXR3)?

JNJ-1900 (NBTXR3) is being studied across multiple solid tumors, led by NANORAY-312, a global randomized Phase 3 trial in locally advanced head and neck squamous cell cancers. Its proof-of-concept came from a successful randomized Phase 2/3 soft tissue sarcoma study reported in 2018, supporting broader development.

What partnerships support Nanobiotix’s NBTXR3 development strategy?

Nanobiotix has a broad clinical collaboration with The University of Texas MD Anderson Cancer Center for multiple Phase 1 and 2 studies. In 2023, it also entered a global co-development and commercialization license agreement for JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 11.3 KB